Toxicity of non-nucleoside analogue reverse transcriptase inhibitors
- PMID: 12800070
- DOI: 10.1055/s-2003-39948
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors
Abstract
The non-nucleoside reverse transcriptase inhibitors (NNRTI) nevirapine (NVP), efavirenz (EFV), and delaviridine (DLV) are increasingly being used to treat HIV infection. Studies have shown excellent tolerance and efficacy and less development of virological resistance with HIV regimens that include NNRTIs. Nevertheless, abnormalities in liver enzymes are common in patients with HIV infection, and there are multiple etiologies for these abnormalities, including drug toxicity, viral hepatitis, opportunistic infections, and substance abuse. In particular, highly active antiretroviral therapy (HAART) can result in hepatotoxicity through a variety of mechanisms, such as mitochondrial toxicity, lipodystrophy syndrome, and steatohepatitis. The NNRTIs have been most frequently implicated in hypersensitivity reactions. NVP-containing HAART regimens may be more hepatotoxic than are those with EFV and DLV, at least for the first 6 weeks, although the data are still contradictory. Coinfection with hepatitis C and B viruses appears to significantly increase the risk of toxicity, and therefore all patients should be screened for viral hepatitis prior to commencing HAART. Close monitoring of transaminases is suggested in all patients commencing HAART, especially those with preexisting liver disease and coinfection with viral hepatitis.
Similar articles
-
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. PMID: 21154355 Updated. Review.
-
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22. Ned Tijdschr Geneeskd. 2006. PMID: 16924943 Review. Dutch.
-
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.HIV Clin Trials. 2005 Nov-Dec;6(6):302-11. doi: 10.1310/EWWC-YLJ6-8LHE-054A. HIV Clin Trials. 2005. PMID: 16452064 Clinical Trial.
-
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.Clin Infect Dis. 2005 Feb 15;40(4):588-93. doi: 10.1086/427216. Epub 2005 Jan 21. Clin Infect Dis. 2005. PMID: 15712082
-
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Hepatology. 2002 Jan;35(1):182-9. doi: 10.1053/jhep.2002.30319. Hepatology. 2002. PMID: 11786975
Cited by
-
Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era.Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076. eCollection 2021 Mar. Open Forum Infect Dis. 2021. PMID: 33738323 Free PMC article.
-
Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans.ACS Pharmacol Transl Sci. 2020 Apr 23;3(4):655-665. doi: 10.1021/acsptsci.0c00015. eCollection 2020 Aug 14. ACS Pharmacol Transl Sci. 2020. PMID: 32832868 Free PMC article.
-
Drug-Induced Liver Injury in HIV Patients.Gastroenterol Hepatol (N Y). 2006 Jun;2(6):430-437. Gastroenterol Hepatol (N Y). 2006. PMID: 28316518 Free PMC article.
-
The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations.Infect Dis Obstet Gynecol. 2015;2015:563727. doi: 10.1155/2015/563727. Epub 2015 Nov 5. Infect Dis Obstet Gynecol. 2015. PMID: 26617456 Free PMC article.
-
Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Pediatric Health Med Ther. 2014 May 29;5:29-42. doi: 10.2147/PHMT.S47794. Pediatric Health Med Ther. 2014. PMID: 25937791 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical